International research team have decoded the genetic blueprint of the tularemia (rabbit fever) bacterium

Two teams of researchers, one based in the United States and the other in Europe, have decoded the genetic blueprint of the tularemia (rabbit fever) bacterium, a highly infectious human and animal pathogen.

The complete genomes of separate strains of Francisella. tularensis were sequenced by scientists at the U.S. Department of Energy's Lawrence Livermore National Laboratory (LLNL) in California and at Uppsala University in Sweden. Also participating were researchers at Porton Down, United Kingdom; the Swedish Defense Agency, Umea, Sweden; the U.S. Center for Disease Control's Division of Vector-Borne Infectious Diseases, Fort Collins, Colo.; and Walter Reed Army Institute of Research, Silver Spring, Md.

"Comparing the genome sequences of the two strains will help us identify the genes, and their associated proteins, that cause one strain of F. tularensis to be more virulent than another," said biologist Emilio Garcia, one of the project leaders for the Laboratory.

Knowledge of the microbe's genome sequence - the precise order of the nucleotide bases in its DNA - can improve scientific understanding of its fundamental physiology and metabolism. The knowledge could help researchers develop more effective vaccines and better methods for detecting, diagnosing and treating tularemia.

Tularemia is a rare but serious disease normally spread by insect bites and human contact with rabbits, prairie dogs, and other small and medium-sized animals. While seldom fatal, and treatable with antibiotics, the disease causes severe, long-lasting pneumonia-like symptoms and a variety of glandular and intestinal disorders. As few as 10 organisms entering the body can cause fever, making tularemia one of the most infectious of all human diseases.

First discovered in 1911, tularemia is an "intracellular" pathogen that invades the body's cells, shuts down their normal immune response, and then multiplies within the body. The bacteria can enter the body through open wounds, inhalation, ingestion, or bites from ticks and deerflies. Signs of pneumonia and fever typically arise 24 to 48 hours after the disease is contracted.

While the virulent SchuS4 strain sequenced by Uppsala University is found primarily in North America, the microbe sequenced by LLNL, known as F. tularensis LVS (Live Vaccine Strain), is more widespread yet less virulent and is found in North America, Europe, and Northeast and Central Asia.

An annual average of about 125 human cases of the disease were reported in the United States in the 1990s. In addition to being found naturally in the environment, F. tularensis is considered a potential biothreat agent. Prompt treatment with antibiotics can head off the worst symptoms of tularemia, which is currently fatal in about 2 percent of reported cases.

The F. tularensis LVS sequence, consisting of about 1.9 million base pairs, is being published on LLNL's website (https://www.llnl.gov/). The F. tularensis SchuS4 sequence is available at
https://ebc.uu.se/?languageId=1. Once they are fully annotated, both sequences will also be submitted to Genbank, the DNA sequence database maintained by the U.S. National Institutes of Health, so they can be accessed and studied by scientists around the world.

The Livermore project was funded by DOE and other U.S. federal agencies, as well as by Laboratory Directed Research and Development funds. The European-American consortium was funded by the U.S. Army Medical Research and Materiel Command, the UK Ministry of Defense, the Swedish Ministry of Defense, and the U.S. Defense Advanced Research Projects Agency.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Patient-derived organoids: Transforming cancer research and personalized medicine